BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage - 2Volunteers aiding humpback whale stranded in Baltic get death threats
- 3How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- 4French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- 5'Senseless violence' erupts at Christmas tree lighting; 4 injured
- Journey Travel Objections for Your Next Experience
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Vote in favor of your Number one method for praising a birthday
- Human evolution’s biggest mystery has started to unravel. How 2025 tipped the scales
- Living Abroad: Social Inundation and Self-improvement
- Germany unveils rescue plan for struggling chemical sector
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- US FDA declines to approve Corcept's drug for rare hormonal disorder
